Will we be able to care for cancer patients in the future?

Oncology

Volumn 24, Issue 14, 2010, Pages

  Bunnell, Craig A ^a   Shulman, Lawrence N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DOCETAXEL; GEFITINIB; IRINOTECAN; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVOR; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG COST; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; PATIENT CARE; REVIEW;

EID: 79551700566     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. National Cancer Institute. Cancer trends progress report 2009-2010 update. Available from: http://progressreport.cancer.gov/doc-detail.asp?pid= 1&did=2009&chid=93&coid=920&mid=#key.
2. American Cancer Society. Cancer Facts & Figures 2010. Available from: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer- facts-and-figures-2010.
3. Data derived from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Reports.ReportsMenu
4. Erikson C, Salsberg E, Forte G, et al. Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Practice. 2007;3:79-86. (Pubitemid 351593695)
5. Warren J, Mariotto A, Meekins A, et al. Current and future utilization of services from medical oncologists. J Clin Oncol. 2008;26:3242-7.
6. Hewitt M, Greenfield S, Stovall E: From cancer patient to cancer survivor: Lost in transition. Washington, DC National Academies Press, 2006.
7. Shulman LN, Jacobs LA, Greenfield S, et al. Cancer care and cancer survivorship care in the United States: will we be able to care for these patients in the future? J Oncol Practice. 2009;5:119-23.
8. Bodenheimer T: Primary care: will it survive? N Engl J Med. 2006;355:861-4.
9. Salsberg E, Grover A. Physician workforce shortages: implication and issues for academic health centers and policymakers. Acad Med. 2006;81:782-7. (Pubitemid 44319113)
10. Goodman D, Fisher E. Physician workforce crisis? Wrong diagnosis, wrong prescription. N Engl J Med. 2008;358:1658-61. (Pubitemid 351549912)
11. Starfield B, Fryer G. The primary care physician workforce: ethical and policy implications. Annals of Family Med. 2007;5:486-91. (Pubitemid 350248579)
12. Earle CC, Nevill BA. Underuse of necessary care among cancer survivors. Cancer. 2004;101:1712-19. (Pubitemid 39314734)
13. Nissen M, Beran M, Lee M, et al. Views of primary care providers on follow-up care and cancer patients. Family Medicine. 2006;39:477-482, 2006.
14. Earle CC, Burstein HJ, Winer EP, et al. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2010;21:1447-51.
15. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966-72.
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2010;355:2542-50. (Pubitemid 44917502)
17. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
18. Jonker DJ, Callaghan C, Karapetis C, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-8. (Pubitemid 350106711)
19. Cohen H. Drug topics Red Book'' 2008. 112th ed. Montvale, NJ: Thomson Healthcare/Thomson PDR; 2008.
20. Press M, Seelig S, Lessons learned from the development of a diagnostic to predict response to Herceptin: targeted medicinefrom concept to clinic. Thomson Financial Street Events, Conference Report on Targeted Medicine. 2004;10-11.
21. Kris M, Natale RB, Herbst R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer. JAMA. 2003;290:2149-58. (Pubitemid 37432975)
22. Giaccone G, Herbst R, Manegold, C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trialINTACT 1. J Clin Oncol. 2004;22:777-84. (Pubitemid 41103588)
23. Herbst R, Giaccone G, Schiller J, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trialINTACT 2. J Clin Oncol. 2004;22:785-794. (Pubitemid 41103589)
24. Mok T, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
25. Mullins CD, Montgomery R, Tunis S. Uncertainty in assessing value of oncology treatments. Oncologist. 2010;15(Suppl 1):58-64.
26. Garber AM, Tunis S. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med. 2009;360:1925-7.